Moreover, the time-dependent ROC analysis revealed that the ISG20 expression had a relatively good performance in predicting 1-year (AUC = 0.84, 95% CI: 0.80–0.88), 2-year (AUC = 0.88, 95% CI: 0.84–0.91), and 3-year OS (AUC = 0.85, 95% CI: 0.80–0.89) in glioma patients (Fig. 4B). This evidence concerns the gene ISG20 and central nervous system cancer.